Outset Medical, Inc. (Nasdaq: OM)
Johnson Fistel, LLP is investigating potential claims on behalf Outset Medical, Inc. (“Outset” or the “Company”) (Nasdaq: OM) against certain of its officers and directors.
If you have continuously owned Outset shares before September 15, 2020, you can click or copy and paste the link below in a browser to join this action:
The action alleges that, throughout the Class Period, Outset misled investors and/or failed to disclose that: (1) the Company had “continuously made improvements and updates to Tablo over time since its original clearance,” which required further studies and potentially new applications to the U.S. Food and Drug Administration (“FDA”); (2) in the absence of such studies and FDA approval, the Company could not conduct a human factors study on the Tablo pursuant to FDA protocols; and (3) Outset’s inability to conduct the human factors study exposed the Company to the risk of FDA actions, including a shipping hold and marketing suspension, rendering Outset incapable of selling Tablo for home use.
About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. Johnson Fistel seeks to recover losses incurred due to violations of federal securities laws. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.
Contact:
Johnson Fistel, LLP
Jim Baker, Lead Securities Analyst
Telephone: (619) 814-4471
Email: jimb@johnsonfistel.com